Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced it has exceeded its initial enrollment target for the stroke registrational program evaluating its Portable Neuromodulation Stimulator (PoNS® ...

Technologies announced positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with ...

PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- ...

Charting, Price Performance, News & Related Contracts.

NEWTOWN, Pa. - Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company with a market capitalization of $2.8 ...

Technologies announced it has completed and far exceeded the initial target enrollment for its stroke registrational ...

Unlike mimics, stroke chameleons are presentations that masquerade as an alternative neurological entity when they are truly ischemic in nature. We present a rare case of bilateral pontine infarcts ...

Computed Tomography (CT) head was negative for ischemic stroke or hemorrhage. Arterial CT showed neither ... An additional small lesion was found on the pons. Patient declined TPA on presentation in ...